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Abstract
Background: The bromodomain and extraterminal domain (BET) family proteins (BET2, BET3, and BET4) “read”
(bind) histone acetylation marks via two distinct bromodomains (Brom1 and Brom2) facilitating transcriptional
activation. These epigenetic “readers” play crucial roles in pathogenic processes such as inflammation. The role of
BETs in influencing the degenerative process in the retina is however unknown.
Methods: We employed the rd10 mouse model (Pde6brd10 mutation) of retinitis pigmentosa (RP) to examine the
involvement of BET proteins in retinal neurodegeneration.
Results: Inhibition of BET activity by intravitreal delivery of JQ1, a BET-specific inhibitor binding both Brom1 and
Brom2, ameliorated photoreceptor degeneration and improved electroretinographic function. Rescue effects of JQ1
were related to the suppression of retinal microglial activation in vivo, as determined by decreased immunostaining
of activation markers (IBA1, CD68, TSPO) and messenger RNA (mRNA) levels of inflammatory cytokines in microglia
purified from rd10 retinas. JQ1 pre-treatment also suppressed microglial activation in vitro, decreasing microglial
proliferation, migration, and mRNA expression of inflammatory cytokines (TNFα, MCP-1, IL-1β, IL-6, and RANTES).
Expression of BET2, but not BET3 and BET4, was significantly elevated during photoreceptor degeneration at
postnatal day (PN)24 in retinas of rd10 mice relative to age-matched wild-type controls. siRNA knockdown of BET2
but not BET4, and the inhibitor of Brom2 (RVX208) but not of Brom1 (Olinone), decreased microglial activation.
Conclusions: These findings indicate that BET inhibition rescues photoreceptor degeneration likely via the
suppression of microglial activation and implicates BET interference as a potential therapeutic strategy for the
treatment of degenerative retinal diseases.
Keywords: Bromodomain and extraterminal domain (BET) proteins, Epigenetic readers, Retinal degeneration,
Microglial activation, JQ1, rd10 mice
Background
Retinitis pigmentosa (RP) is a major blinding disease
characterized by photoreceptor degeneration arising
predominantly from mutations in genes expressed in
photoreceptor or RPE cells [1, 2]. Despite extensive
studies and trials of various means, e.g., antioxidants and
stem cell therapy, to preserve or replace photoreceptors
in RP, few effective clinical treatments are currently
available [2]. Recently, gene correction or gene therapy
has shown promise to treat RP [1, 3]. However, the
significant number (>170) of RP-causative genes [4] is a
sobering reminder that it is imperative to identify and
target a common mechanism or regulator shared by
various RP etiologies.
Neuroinflammation is now considered a hallmark of
many neurodegenerative disorders [5]. Hyper-activation
of microglia, a class of innate immune cells, was recently
demonstrated to be an important contributor to
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photoreceptor neurodegeneration in the rd10 (Pde6b)
model of RP [6]. Most recently, a report using the rd10
model discovered a positive feedback mechanism
whereby activated microglia migrate to and phagocytose
non-apoptotic photo-receptors and then become even
more activated, profoundly accelerating the loss of both
non-apoptotic and apoptotic photoreceptors [7]. Signifi-
cantly, pathogenic microglial activation is associated
with photoreceptor loss not only in RP but also age-re-
lated macular degeneration and diabetic retinopathy in
animal models and human patients [8]. Thus, blocking
microglial over-activation emerges as an appealing strat-
egy to improve photoreceptor survival across various
etiologies of retinal degeneration. However, poor under-
standing of the molecular mechanism(s) underlying
microglial activation, particularly in the retina, poses a
major barrier to applying this strategy [8].
Recent groundbreaking studies suggest that the
bromodomain and extraterminal domain (BET) family of
epigenetic “readers” is a powerful regulator in pathogen-
esis involving inflammation [9–11]. For BET family
proteins, hereafter referred to as BET2, BET3, and BET4
(BRDs in the literature) [12], each contains two distinct
bromodomains (denoted as Brom1 and Brom2 in this
report) and an extraterminal domain. They “read,” i.e.,
recognize and bind, acetylation marks on histones and/
or on transcription factors via their bromodomains and
“translate” the chromatin marking into gene expression
by activating transcriptional machinery [12]. The BET
family was widely viewed as undruggable, until the
serendipitous discovery of the first-in-class inhibitor JQ1
[13], and subsequently its derivatives that specifically
block BET bromodomains [14]. Importantly, BET
bromodomain blockade effectively mitigates cancers and
inflammatory diseases. Several BET inhibitors have
quickly entered clinical trials and shown encouraging re-
sults [14]. Of particular relevance to the current study,
BET inhibitors abrogate the activation of macrophages
[9, 15]. These adaptive immune cells share many charac-
teristics with microglia [16], raising a question as to
whether the BET family also plays a role in microglial
activation. In support of this, a new report shows that
JQ1 mitigates the expression of inflammatory cytokines
in the BV-2 microglial cell line [17]. However, the spe-
cific roles of BET proteins and their bromodomains in
the activation of microglia in the retina, and in RP, are
not known.
The current report is the first to address the role of
the BET family in retinal degenerative disease. We asked
whether blocking the BET family with JQ1 promotes
photoreceptor survival in a well-established RP model
(rd10 mice). We then determined the JQ1 effect on
microglial activation, as this pathogenic process is
known to greatly exacerbate photoreceptor loss in rd10
mice [6, 7]. Our data indicate that JQ1 treatment abro-
gates microglial activation in vitro, and in vivo in the
rd10 retina, and also effectively preserves rd10 mouse
photoreceptor cell survival and function. These results




All animal procedures conformed to the NIH guide for
the ethical care and use of laboratory animals and were
in compliance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Animal
protocols were approved by the Institutional Animal
Care and Use Committee of the University of
Wisconsin-Madison. All surgeries were performed under
isoflurane anesthesia (inhalation at 2 ml/min flow rate),
and every effort was made to minimize animal suffering.
Animals were euthanized in a chamber gradually filled
with CO2. Wild-type (WT; C57BL/6) and rd10 mice
were purchased from the Jackson Laboratory (Bar Har-
bor, ME). Animals were maintained on a 4% fat diet
(8604 M/R, Harkland Teklad, Madison, WI) and sub-
jected to standard light cycles (12 h/12 h light/dark).
Intravitreal injection of JQ1 in rd10 mice
To test the effect of BET bromodomain blockade in vivo,
2 μl of JQ1 (0.1 mM dissolved in 10% DMSO in PBS) or
vehicle (10% DMSO in PBS) was intravitreally injected
into rd10 or WT mice at PN14. WT mice were only
injected with vehicle. Each rd10 mouse received JQ1 in
one eye (left or right, randomly assigned) and vehicle in
the contralateral control eye. At time points indicated in
figures, animals were either subjected to ERG measure-
ments or euthanized for preparation of retinal homoge-
nates or PFA-fixed sections. Animals that developed
complications from the injection procedure (e.g., ocular
infection, inflammation) were excluded from the ana-
lysis. This criterion was pre-established and involved
<5% of treated animals. The experiments were per-
formed independently at least three times.
Electroretinogram recordings
Ten days after intravitreal injection (PN24) of vehicle or
JQ1 in rd10 mice, ISCEV standard full-field flash ERG
was performed using HMsERG system (OcuScience,
Henderson, NV) following our published method [18].
Mice were dark-adapted overnight and anesthetized with
intraperitoneal ketamine (90 mg/kg) and xylazine (8 mg/
kg) under dim-red illumination. After topical application
of tropicamide (1%, Alcon) and phenylephrine (2.5%,
Alcon) for pupillary dilation and proparacaine hydro-
chloride (0.5%, Alcon) for topical anesthesia, stainless
steel subdermal needle electrodes were placed for
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ground (at the tail) and under individual eye lids as
reference electrodes. Rodent 2.5-mm contact lens with
silver-embedded thread electrode were placed on the
cornea of each eye using Goniovisc hypromellose 2.5%
ophthalmic lubricant solution (HUB Pharmaceuticals,
CA). Flash ERG recordings were obtained simultan-
eously from both eyes at increasing light intensities from
0.03 to 30 cd s/m2 (saturating intensity in our reported
studies [18]) under dark-adapted conditions. The stimu-
lus interval between flashes varied from 20 s at the
lowest stimulus strengths to 60 s at the highest ones.
Two to 10 responses were averaged depending on flash
intensity. ERG signals were sampled at 1 kHz and
recorded with 0.3 Hz low-frequency and 300 Hz high-
frequency cutoffs. Analysis of a-wave and b-wave ampli-
tudes was performed using ERGView analytical software
(OcuScience, Henderson, NV) that digitally filters out
high-frequency oscillatory potential wavelets. The a-
wave amplitude was measured from the baseline to the
negative peak, and the b-wave was measured from the a-
wave trough to the maximum positive peak and plotted
using Origin.
Preparation of retinal sections and homogenates
At various time points after injection (PN14, 18, 21, 24,
30), animals were euthanized by CO2 asphyxiation
followed by cervical dislocation. Eyeballs were immedi-
ately enucleated and dissected. For morphometric and
immunohistochemistry analyses, eyeballs were fixed in
4% paraformaldehyde for 7 h at 4 °C, and then used for
preparation of paraffin-embedded sections or cryosec-
tions, according to our published methods [19]. Briefly,
for cryosections, eyeballs were soaked in 30% sucrose in
PBS for 14 h at 4 °C and 10-μm sections were cut from
the eyeballs frozen in an optimum cutting temperature
(OCT) embedding medium (Sakura Finetek 4583;
Sakura Finetek USA, Inc., Torrance, CA). For paraffin-
embedded sections, eyeballs were dehydrated by etha-
nol/xylene after fixation and embedded in paraffin. Ten-
micrometer-thick sections were prepared for immuno-
histochemistry. For Western blotting and quantitative
real-time PCR (qRT-PCR) determination, tissue homog-
enates were prepared from unfixed retinas.
Photoreceptor counting in the outer nuclear layer
The number of photoreceptors on retinal paraffin
sections was evaluated by counting H&E-stained nuclei
in the outer nuclear layer (ONL) following our published
method with minor modifications [7]. Briefly, for each
section, the central, middle, and peripheral regions were
defined as 0–1000 μm, 1000–2000 μm, and greater than
2000 μm from the optic nerve head, respectively. Nuclei
were manually counted in each (100 μm length of retina)
of the three fields chosen in the central, middle, and
peripheral regions of the ONL. The counts from all
three to four sections of the same eye were averaged,
and the means from six to nine animals were then aver-
aged to calculate the mean and standard error of the
mean (SEM) for each group of animals.
Immunohistochemistry for assessment of protein levels of
BETs in the retina
Immunostaining was performed on paraffin-embedded
retinal sections following our published method [19].
Briefly, sections were first incubated with each of the
primary antibodies for 1 h: rabbit anti-BET2 (1:150,
Abcam, 139690, Cambridge, MA); rabbit anti-BET4
(1:200, Abcam, 128874); mouse anti-BET3 (1:200,
Abcam, 56342). Sections were then incubated with Imm-
PRESS HRP-conjugated goat-anti-rabbit (or mouse) sec-
ondary antibody (1:200, Vector Laboratories), followed
by visualization with 3,3′-diaminobenzidine (DAB) and
counterstaining with hematoxylin. Sections stained with
the secondary antibody, but not a primary antibody,
were used as a background control.
Immunohistochemistry and fluorescence microscopy for
assessment of retinal microglial distribution
Immunostaining was performed on retinal cryosections
following our previously described method [20] with
minor modifications. Briefly, retinal sections were
permeabilized with 1% Triton X-100 in PBS for 20 min,
blocked with 10% normal donkey serum (017-000-121;
Jackson Immunoresearch Lab, MS) for 2 h at room
temperature, and then incubated with a primary
antibody overnight at 4 °C. Sources and dilutions of
primary antibodies are the following: rabbit anti-IBA-1
(Waco, 019-19741), 1:400; rabbit anti-CD68 (Millipore,
MAB3402), 1:200; rabbit anti-TSPO (Abcam, 109497,
Cambridge, MA), 1:200. After rinsing the section three
times, a secondary antibody (Alexa-488 conjugated
donkey-anti-rabbit or Alexa-594-conjugated donkey-
anti-mouse) at 2 μg/ml was applied at room temperature
for 2 h. Sections were then rinsed three times, counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) for
5 min, and then mounted in Prolong Gold mounting
medium (Invitrogen, Carlsbad, CA) and cover-slipped.
The slides were left in the dark overnight and then
sealed using clear nail polish (Electron Microscopy
Sciences, Hatfield, PA). Images were acquired with a
Nikon Eclipse Ti microscope with a DS-Qi1 camera
using ×20 or ×40 objective lens and analyzed by Nikon
Elements software. Immuno-fluorescence from the
central, middle, and peripheral regions was quantified
manually. Cell counts from all three to four sections of
the same eye were averaged, and the means from six to
nine animals were then averaged to calculate the mean
and SEM for each group of animals. Sections stained
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with a secondary antibody, but not a primary antibody,
were used as background control.
TUNEL labeling and caspase-3/7 activity assay
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay was performed using an In Situ
Cell Death Detection Fluorescein or TMR red kit
(Roche, Indianapolis, IN, USA). The TMR red kit was
used for co-staining of other markers. TUNEL staining
was performed on retinal cryosections and imaged to as-
sess DNA fragmentation as an indicator of apoptosis.
TUNEL-positive cells were quantified in three fields
from three to four sections per eye. Each field repre-
sented a 500-μm retinal length in the central, middle,
and peripheral regions. Cells were scored as either posi-
tive or negative. The counts from all sections of the
same animal were averaged for a per animal mean, and
the means from six to nine animals were averaged to
generate the mean and SEM for the entire group of
animals.
A Caspase-Glo 3/7 assay kit (Promega, Madison, WI)
was used to determine the relative activity of caspase-3/
7 according to manufacturer’s instructions. Briefly, in a
96-well plate, retinal homogenates were incubated with
50 μl Caspase-Glo 3/7 reagent and 50 μl PBS (per well).
Plates were incubated at room temperature for 1 h and
read in a FlexStation 3 Benchtop Multi-Mode Micro-
plate Reader (Molecular Devices, Sunnyvale, CA).
Microglia isolation and purification from rd10 mouse
retinas
JQ1 or vehicle was intravitreally injected to rd10 mice
at PN14, as described above. After 10 days, retinal
microglial cells were isolated and purified, following
our published method with minor modifications [7].
Briefly, animals were euthanized and their eyeballs enu-
cleated immediately. The globes were dissected free of
periocular connective tissues and rinsed with HBSS
buffer. The anterior segment and vitreous were
removed, and the retina was dissected free from the
underlying RPE layer. The retinas were transferred into
DMEM containing 70 U/ml collagenase (0.5 ml per
eye) and incubated at 37 °C for 60 min. Enzyme activity
was terminated using DMEM containing 10% FBS. The
retinas were dissociated mechanically and passed
through 40-μm nylon mesh (Corning, NY). The dissoci-
ated cells were then labeled with antibodies for CD11b
(BD, 557397) and CD45 (BD, 559864) and DAPI.
Microglial cells were purified by flow sorting (CD11b
positive and CD45 low) and a >95% purity was
achieved. Cells were used immediately for RNA isola-
tion and qRT-PCR.
Microglia isolation and purification from B6 mouse brains
Primary microglial cells were prepared as we described
previously [21]. Briefly, brains from 3–5-day-old mice
were dissected and dissociated with 0.25% trypsin sup-
plemented with EDTA followed by trituration with a
Pasteur pipette until a single cell suspension was ob-
tained. Cells were resuspended in DMEM supplemented
with 10% FBS and 100 units/ml penicillin/streptomycin
and plated in 80-mm2 cell culture flasks. After 10–
12 days, flasks were gently shaken for 1 h and the
medium was harvested and centrifuged for 10 min to
collect microglia.
Real-time quantitative PCR assay for expression of
inflammatory cytokines
RNA was extracted from retinal homogenates or cells
using Trizol (QIAGEN, Valencia, CA) following the
manufacturer’s instructions. Purified messenger RNA
(mRNA) (1 μg) was used for the first-strand comple-
mentary DNA (cDNA) synthesis using iScript cDNA
synthesis kit (Bio-Rad) and quantitative RT-PCR was
performed using the 7500 Fast Real-Time PCR System
(Applied Biosystems, Carlsbad, CA), as described in our
previous report [22]. Real-time quantitative PCR (qRT-
PCR) data with a high cycle number (e.g., >35) was not
considered. Each cDNA template was amplified in tripli-
cate using SYBR Green PCR Master Mix (Applied Bio-
systems, Carlsbad, CA).
Enzyme-linked immunosorbent assay for MCP-1 protein
production
ELISA was performed to evaluate MCP-1 protein pro-
duction in microglial cells, using an MCP-1 ELISA kit
based on the sandwich enzyme immunoassay technique
(R&D Systems, Minneapolis, MN, USA). The absorbance
was determined using a Flex Station 3 microplate reader
(Molecular Devices, Sunnyvale, CA, USA).
N9 microglial cell culture, pre-treatment with BET inhibitors,
and LPS stimulation
Mouse N9 microglial cells were kindly provided by Dr.
Paula Ricciardi-Castagnoli [23] and grown in the same
medium described above for primary microglial cells.
Cells were plated at a density of 120,000 cells/well on
12-well plates and used for experiments the following
day. (+)-JQ1 (Cayman Chemicals, Ann Arbor, MI, USA),
Olinone (Cat. GLXC-05021, Glixx Laboratories, South-
borough, MA, USA), and RVX208 (Apexbio, Houston,
TX, USA) were dissolved in dimethyl sulfoxide (DMSO,
Sigma-Aldrich, St. Louis, MO, USA) for preparation of
stock solutions, which were then diluted in DMEM for
experiments. The final concentration of DMSO in the
medium was less than 10 μL/10 mL, which did not show
any effect on cell growth. To identify appropriate
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concentrations of BET inhibitors for various experi-
ments, we performed dose response pilot studies. N9
cells were pre-treated with BET inhibitors at various
concentrations for 12 h, and then subjected to CellTiter-
Glo viability assay, as described in our previous report
[22]. We chose 0.5, 30, and 30 μM for JQ1, Olinone, and
RVX208, respectively, as these represent the maximal
concentrations that did not compromise N9 cell viability
(Additional file 1: Figure S6). For experiments to evalu-
ate the effect of BET inhibitors on lipopolysaccharide
(LPS)-stimulated phenotypes of activated microglia (N9
or primary cells), cells were pre-treated with JQ1, Oli-
none, or RVX208 for 12 h and then stimulated with LPS
(1 μg/mL, Sigma-Aldrich, St. Louis, MO, USA) for 2 h
followed by various assays as described below in detail.
N9 microglia cell proliferation assay (BrdU)
To study the effect of BET inhibitors on the proliferation
of N9 microglial cells, we used a Cell Proliferation BrdU
ELISA (colorimetric) Kit (Roche Applied Science, In-
dianapolis, IN) following manufacturer instructions, as
described in our previous study [22] with minor modifi-
cations. Briefly, N9 cells were seeded in 96-well plates at
a density of 4000 cells per well with a final volume of
200 μl, in DMEM containing 0.5% FBS. Cells were pre-
treated with 0.5 μM JQ1, 30 μM Olinone, 30 μM
RVX208, or an equal volume of vehicle control (DMSO)
for 12 h prior to LPS stimulation (final 1 μg/ml). After
LPS treatment for 2 h, cells were labeled with BrdU in
DMEM containing 10% FBS for a 2-h incubation at 37 °
C, and then fixed with a FixDenat solution for 30 min,
followed by a 90-min incubation at room temperature
with an anti-BrdU-POD antibody (1:100 dilution). After
washing with PBS three times, substrate was added.
Plates were incubated at room temperature for 30 min,
and colorimetric signals were measured on a FlexStation
3 Benchtop Multi-Mode Microplate Reader (Molecular
Devices, Sunnyvale, CA) at 370 nm with a reference
wavelength of 492 nm.
N9 microglia cell migration assay (Transwell)
Assay was performed according to our previously re-
ported method [22]. Briefly, N9 cells were seeded at a
density of 20,000/well in the upper chamber of Trans-
well Permeable Supports (or Inserts) (8 μm pore size,
Corning, NY) placed in 24-well plates. Cells were pre-
incubated with 0.5 μM JQ1, 30 μM Olinone, and 30 μM
RVX208 or vehicle (DMSO) for 12 h prior to LPS stimu-
lation (final 1 μg/ml). Inserts were harvested at 24-h
post stimulation and fixed in 70% ethanol at −20 °C for
30 min. Pre-moistened cotton swabs were used to gently
scrape remaining cells in the upper chamber of inserts,
followed by staining the cells on the lower surface of the
insert in hematoxylin solution for 30 min at room
temperature. The upper chamber of the inserts was
swabbed again and rinsed twice with PBS. After air-
drying the inserts for 30 min, the polyester membranes
were harvested using a scalpel and mounted on glass
slides using 90% glycerol. Images were then taken to
quantify cells that migrated across the membrane from
the upper chamber to the lower surface.
siRNA knockdown of BET proteins
Knockdown was performed as described in our previous
report [22]. Lentiviruses for expression of scrambled or
mouse BET-specific siRNAs were packaged using a
three-plasmid expression system including piLenti-
siRNA-GFP, psPAX2, and pMD2.G (Addgene, Cam-
bridge, MA). The piLenti-siRNA-GFP vectors for
expression of a scrambled siRNA or siRNAs specific for
mouse BET2 or BET4 were purchased from Applied
Biological Materials Inc. (Canada).










The three plasmids were co-transfected into HEK293T
cells in DMEM medium containing 1% FBS using a Jet-
Prime Polyplus-transfection reagent (Polyplus-transfec-
tion Inc., New York, NY) following the manufacturer’s
protocol. After transfection for 24 h, the medium con-
taining transfection reagents was replaced with fresh
DMEM medium containing 1% FBS. The culture
medium was collected after 24-h incubation and passed
through a 0.45-μm filter (EMD Millipore, MA) and then
concentrated and titrated using Lenti-X™ Concentrator
and Lenti-X™ qRT-PCR Titration Kit (Clontech Labora-
tories, Inc., Mountain View, CA). The lentivirus prepar-
ation was then applied to the N9 microglial cell culture
together with 8 μg/ml polybrene and incubated for 24 h.
Infected (green fluorescent) cells were recovered in fresh
DMEM medium containing 1% FBS for 3 days and sub-
jected to flow sorting. Sorted cells were cultured for 2–
3 days and then used in Western blotting or qRT-PCR
assays.
Western blotting for assessment of BET protein levels
Retinal homogenates or cells were solubilized in RIPA
buffer containing protease inhibitors (50 mM Tris,
150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl
sulfate, and 10 μg/ml aprotinin). Protein concentrations
of cell lysates were determined using a Bio-Rad DC™
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Protein Assay kit. Approximately 15–30 μg of proteins
from each sample was separated on 4–20% Mini-
PROTEAN TGX precast gels (Bio-Rad) and transferred
to PVDF membrane. Proteins of interest were detected
by immunoblotting using the following primary anti-
bodies and dilution ratios: rabbit anti-BET2 (1:1000)
from Abcam (ab139690) and Bethyl laboratories (A302-
583A), mouse anti-BET3 (1:1000) from Abcam (56342),
rabbit anti-BET4 (1:1000) from Abcam (128874), and
mouse anti-β-actin from Sigma-Aldrich. After incuba-
tion with HRP-conjugated secondary antibodies (1:5000,
goat anti-rabbit or mouse, Bio-Rad), specific protein
bands on the blots were visualized by applying enhanced
chemiluminescence reagents according to the manufac-
turer’s instructions (Pierce, Rockford, IL) and then re-
corded with a LAS-4000 Mini imager (GE, Piscataway,
NJ). Band intensity was quantified using ImageJ.
Statistical analysis
The required sample sizes in animal experiments were
calculated based on estimates of mean differences, vari-
ances, and power. Statistically significant differences be-
tween treatment groups were determined by one-way
ANOVA (SPSS software, v.13.0, Chicago, IL) using the
Bonferroni multiple comparison post hoc test or a two-
tailed t test for grouped comparison. Significance was
set at P < 0.05.
Results
Blocking BETs with JQ1 preserves photoreceptor number
and function in rd10 mice
The discovery of JQ1, the first-in-class inhibitor of the
BET family [13], has opened unprecedented opportun-
ities for studying the function of BET proteins in various
diseases. While each BET protein contains two distinct
bromodomains (Brom1 and Brom2), JQ1 binds to both
in all three BETs [24]. JQ1 is a designer drug that is
highly specific to the BET family as demonstrated in the
studies against 46 non-BET bromodomains [13, 14, 25].
Thus, we used JQ1 to determine whether specifically
blocking bromodomains of the BET family ameliorates
photoreceptor loss. JQ1 and vehicle (DMSO) were
injected, respectively, into the right (or left) eye and the
contralateral eye of rd10 mice (PN14). Eyeballs were col-
lected at PN18, PN21, PN24, PN27, and PN30 for the
preparation of retinal sections, and photoreceptor num-
bers were counted in the outer nuclear layer (ONL)
(Fig. 1a, Additional file 1: Figure S1). As shown in Fig. 1b,
whereas photoreceptors continuously decreased from
PN18 through PN30 in rd10 mice injected with vehicle,
the photoreceptor number was at least 90% preserved
until PN24 and then declined at later time points in
rd10 mice injected with JQ1. The most prominent JQ1
protective effect was observed at PN24, the peak time of
photoreceptor degeneration in rd10 mice [6].
We next determined the effect of JQ1 treatment on
retinal function via electroretinogram (ERG) recording
at PN24 (Fig. 1c). We found that the photoreceptor
light response measured as the a-wave amplitude in
vehicle-treated rd10 mice was completely obliterated
at all flash intensities as expected for rd10 mice ERG
responses, indicating loss of photoreceptor function.
ERG a-wave amplitudes for JQ1-treated rd10 mouse
retinas showed an increase in amplitude with incre-
mental flash intensities (at least threefold increase at
10 and 30 cd s/m2) implying partial rescue of photo-
receptor light response (Fig. 1d). In contrast to
vehicle-treated mice, JQ1-treated rd10 mice showed
significantly preserved inner retina (ON-bipolar and
Muller cell) b-wave amplitudes (doubled) at all flash
intensities. The integrity of inner retina is also
reflected by preserved oscillatory potential (OP) re-
sponse overlapping b-waves (Fig. 1c). These results
agree with the morphometric data in Fig. 1b suggest-
ing a protective effect of BET blockade on photorecep-
tor survival.
To further confirm the retinal protective effect of
JQ1, we assessed apoptosis (Fig. 2, Additional file 1:
Figure S2), either by TUNEL staining on retinal sec-
tions, or by caspase-3/7 activity assay using retinal
homogenates. Consistent with previous reports [26,
27], TUNEL-positive cells in vehicle-treated rd10 ret-
inas continuously increased from PN18 to PN24 and
then decreased at later time points. In contrast, JQ1
treatment significantly reduced TUNEL-positive cells
in ONL during PN21-PN24 and appeared to have
shifted or delayed the time course of photoreceptor
apoptosis compared to vehicle control (Fig. 2b). Ac-
cordantly, JQ1 significantly reduced retinal caspase-
3/7 activity at PN24 (Fig. 2c). As shown in Fig. 2d,
essentially all TUNEL-stained nuclei are found in
recoverin (photoreceptor marker)-positive cells, indi-
cating photoreceptor apoptosis characteristic of rd10
mice [26]. Moreover, the lack of overlap between
TUNEL-stained nuclei and IBA1-positive cells also
supports the conclusion that apoptosis occurred
mainly in photoreceptor cells rather than in micro-
glia. Taken together, our data indicate that blocking
BET bromodomains in the rd10 retina via intravit-
real injection of JQ1 preserves photoreceptor num-
ber and function and reduces (or delays) its
apoptosis. The decrease of JQ1 protective effects at
later time points likely stems from the fact that the
JQ1/BET binding is reversible and dissociated JQ1
can diffuse out or decompose [13]. We used 0.1 mM
JQ1 for intravitreal injection throughout the in vivo
experiments because higher concentrations (0.5 and
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2 mM) did not provide greater protective effect
(Additional file 1: Figure S4).
Blocking BETs with JQ1 mitigates microglial activation in
the rd10 mouse retina
Recent studies showed that microglial activation plays
an important role in retinal photoreceptor loss in
rd10 mice [6, 7]. In parallel, an in vitro study found
that JQ1 treatment inhibits lipopolysaccharide (LPS)-
stimulated inflammation in the BV-2 microglial cell
line [17]. However, it remains unknown whether
blocking the BET family with JQ1 suppresses micro-
glial activation in vivo in the degenerating rd10
mouse retina. To address this question, we performed
immunostaining of microglial markers [7] IBA1,
TSPO, and CD68 on retinal sections (Fig. 3a–c). At
PN24, there was a dramatic increase of these
microglial marker proteins in the photoreceptor re-
gion (ONL) compared to B6 controls (Fig. 3d), sug-
gesting microglial proliferation and migration from
inner layers [6, 7], both characteristic of microglial
activation. JQ1 treatment substantially reduced cells
positively stained for these marker proteins (Fig. 3d,
Additional file 1: Figure S3), suggesting a decrease of
activated retinal microglia.
To determine the gross effect of JQ1 on retinal inflam-
mation, we used retinal homogenates of rd10 mice
treated by intravitreal injection of vehicle or JQ1. As
shown in Fig. 4a, whereas inflammatory cytokine (TNFα,
MCP-1, IL-1β, IL-6, and RANTES) mRNAs in the rd10
retina markedly increased compared to B6 controls, JQ1
treatment effectively reduced their expression to basal
WT (B6) levels. This result was also supported by ELISA
assay of MCP-1 protein levels (Fig. 4b).
Fig. 1 JQ1 treatment preserves photoreceptor number and function in rd10 mice. Vehicle (DMSO) and JQ1 (0.1 mM) were intravitreally injected,
respectively, into one eye and the contralateral eye of rd10 mice at PN14. WT (B6) mice were injected only with vehicle. At PN18, PN21, PN24,
PN27, and PN30, mice were either subjected to ERG measurements, or sacrificed for preparation of retinal sections. a Representative H&E-stained
retinal paraffin sections showing a protective effect of JQ1 on ONL thickness in rd10 mice. OS/IS outer/inner segment, ONL outer nuclear layer, INL
inner nuclear layer, GCL ganglion cell layer. Scale bar 50 μm. For images of PN21 and PN27, see Additional file 1: Figure S1. b Quantification for a:
photoreceptor cell number per 100 μm ONL length; mean ± SEM, n = 6 mice; **P < 0.01 compared to rd10 vehicle control. c Representative ERG
traces (measured at PN24, in response to 0.3, 3, or 30 cd s/m2 light intensity of flashes) showing rescue of rd10 mouse retinal function by JQ1
treatment. d Quantification of a-wave and b-wave amplitudes. ERG a-wave is the downward deflected negative response; b-wave is from the a-
wave peak to positive response peak. Oscillatory potential is visible superimposed on b-wave. Data are presented as mean ± SEM, n = 10 mice, *P
< 0.05, **P < 0.01 compared to rd10 vehicle control
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We then assessed the effect of JQ1 specifically on
retinal microglia inflammation, using retinal micro-
glial cells directly purified (by sorting, Additional file
1: Figure S5) from rd10 mice treated with JQ1 or ve-
hicle. We found that the expression of inflammatory
cytokines was significantly (except RANTES) reduced
in JQ1-treated retinal microglia compared to vehicle
control (Fig. 4c). The manipulations during cell
isolation and purification may have inevitably damp-
ened the JQ1 effect on the expression of inflamma-
tory cytokines.
To further confirm the anti-inflammatory effect of JQ1
specifically on microglia, we used primary microglial cell
cultures, derived from whole mouse brain, which is an
abundant source of microglial cells. We found that in re-
sponse to LPS stimulation, inflammatory cytokines
Fig. 2 JQ1 treatment inhibits apoptosis in the rd10 mouse retina. Intravitreal injection of JQ1 (or vehicle) was performed at PN14, as described in
Fig. 1. Eyeballs were collected at PN18, PN21, PN24, PN27, and PN30. Cryosections were prepared and used for TUNEL staining. a Representative
TUNEL (green) images showing an inhibitory effect of JQ1 in rd10 retinas. Scale bar 50 μm. Blue: DAPI staining of nuclei. For images of PN21 and
PN27, see Additional file 1: Figure S2. b Quantification of TUNEL-positive cells (per 500 μm ONL length): mean ± SEM, n = 6 mice; **P < 0.01, *P < 0.05
compared to rd10 vehicle control. c Caspase-3/7 activity assay showing an inhibitory effect of JQ1 on retinal cell apoptosis. For the assay, homogenates
were prepared from retinas collected and pooled from six mice at PN24. **P < 0.01 compared to rd10 vehicle control, n = 3 independent
assay experiments. d For TUNEL/IBA1 and TUNEL/Recoverin co-staining (PN24 retinas), a TMR red kit (Roche) was used so that TUNEL-
positive nuclei appear red. The data show that TUNEL-positive nuclei do not overlap with IBA1-positive cells; instead, they are localized
within recoverin-positive (photoreceptor) cells. Scale bar 50 μm
Zhao et al. Journal of Neuroinflammation  (2017) 14:14 Page 8 of 15
TNFα, MCP-1, IL-1β, IL-6, and RANTES were all dra-
matically upregulated, and JQ1 pre-incubation signifi-
cantly reduced LPS-stimulated expression of all these
cytokines (Fig. 4d).
These different lines of evidence collectively suggest a
prominent role of the BET family in microglial activation
in the degenerating retina of rd10 mice.
Blocking BETs abrogates inflammation, proliferation, and
migration of N9 microglial cells
To further analyze the role of BET proteins in microglial
activation in a systematic manner, we used N9 cells, a
commonly used microglial cell line originally provided by
Dr. Paula Ricciardi-Castagnoli [23]. Using a cell line
allowed us to perform genetic modifications, e.g., knock-
down, and assess major pathogenic phenotypes of
activated microglia, including inflammation, proliferation,
migration, and elevated expression of inflammatory fac-
tors. As shown in Fig. 5a, while LPS potently stimulated
the expression of inflammatory cytokines (TNFα, MCP-1,
IL-1β, IL-6, and RANTES), JQ1 pre-treatment abolished
this LPS-stimulated phenotype of activated microglia. Fur-
thermore, JQ1 pre-treatment reduced N9 cell proliferation
and migration by ~70% (Fig. 5b, c). We used a concentra-
tion of 0.5 μM JQ1 based on an N9 cell viability dose-
response (Additional file 1: Figure S6).
Thus, these combined data from the N9 cell line are
consistent with the results that blocking BET bromodo-
mains with JQ1 effectively suppresses microglial activa-
tion in the rd10 retina (Figs. 3 and 4).
The BET inhibitors thus far developed are not se-
lective within the BET family. JQ1 is highly specific to
the BET family, but binds with similar affinities to
both bromodomains (Brom1 and Brom2) of all family
members [24]. After establishing the inhibitory effect
of JQ1 on microglial activation, we further explored
which bromodomain (Brom1 or Brom2) is the primary
functional site responsible for the observed JQ1 effect
using inhibitors specific to either Brom1 or Brom2.
While Brom2 blocker RVX208 [28] abrogated major
phenotypes of activated microglia (inflammation, pro-
liferation, and migration), Brom1 blocker Olinone [29]
effectively inhibited N9 cell migration, but not prolif-
eration (Fig. 5b, c). Moreover, while RVX208 abolished
the expression of all the tested inflammatory cyto-
kines, Olinone blocked LPS-stimulated upregulation
of RANTES, indicating functional activity of the drug,
but it had no effect on the mRNA expression of TNFα,
MCP-1, IL-1β, and IL-6 (Fig. 5a).
Taken together, these results demonstrate that BET
epigenetic readers play an essential role in microglial ac-
tivation, and that the two bromodomains may have dif-
ferential functions in this pathogenic process.
Fig. 3 JQ1 treatment inhibits retinal microglial activation in the rd10 retina. Intravitreal injection of JQ1 (or vehicle) was performed at PN14, as
described in Fig. 1. Eyeballs were collected at PN18, PN24, and PN30. Cryosections were used for immunostaining and fluorescence microscopy.
a–c Representative immunostaining images of microglial markers. Scale bar 50 μm. Blue DAPI staining of nuclei. d Quantification: IBA1, CD68, or
TSPO positive cells per 500 μm ONL length; mean ± SEM, n = 6 mice. Quantification of IBA1 staining at all five time points (PN18-PN30) is
presented in Additional file 1: Figure S3
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Fig. 5 JQ1 pre-treatment inhibits N9 microglial cell inflammation, proliferation, and migration. N9 microglial cells were pre-incubated with vehicle
(DMSO), JQ1 (0.5 μM), RVX208 (30 μM), or Olinone (30 μM) for 12 h followed by stimulation with LPS (1 μg/ml) for another 2 h, and then
subjected to qRT-PCR (a) for determination of inflammatory cytokine expression. Proliferation assay (b, BrdU ELISA) and migration assay
(c, Transwell) were performed after incubation for additional 24 h. Quantification: mean ± SEM; n = 3 experiments; *P < 0.05, **P < 0.01
compared to vehicle + LPS
Fig. 4 JQ1 treatment inhibits microglial expression of inflammatory cytokines in the rd10 retina. Intravitreal injection of JQ1 (or vehicle) was
performed at PN14, as described in Fig. 1. Retinas were collected at PN24. a Homogenates were prepared from retinas (3 groups, total 12 mice)
and used for qRT-PCR. Quantification: normalization to GAPDH mRNA; mean ± SEM; n = 3 independent homogenation/qRT-PCR
experiments; *P < 0.05, **P < 0.01 compared to rd10 vehicle control. b Retinal homogenates were used for determination of MCP-1 protein levels by
ELISA. Quantification: normalization to WT mice injected with vehicle; mean ± SEM; n = 3 experiments; *P < 0.05. c Retinal microglia were purified from
dissociated rd10 retinas via flow sorting, as described in “Methods”. Sorting was performed five times using retinas collected from five groups of rd10
mice (four mice each). Sorted microglial cells (CD11b + CD45low) were then subjected to qRT-PCR. Quantification: normalization to GAPDH mRNA;
mean ± SEM; n = 5; *P < 0.05, **P < 0.01, compared to rd10 vehicle control. d Microglial cells were isolated and purified from B6 mouse brains. Cells
were pre-incubated with vehicle (DMSO) or JQ1 (0.5 μM) for 12 h, and then induced for inflammatory cytokine expression with LPS (1 μg/ml) for
another 2 h prior to qRT-PCR assay. Quantification: normalization to GAPDH mRNA; mean ± SEM; n = 3 independent experiments; *P < 0.05, **P < 0.01
compared to vehicle + LPS
Zhao et al. Journal of Neuroinflammation  (2017) 14:14 Page 10 of 15
BET2 but not BET3 and BET4 is upregulated in the retina
of rd10 mice compared to wild-type mice; BET2 but not
BET4 knockdown effectively inhibits N9 microglial cell
inflammation
As JQ1 is BET-specific but does not discriminate be-
tween BET family members, we analyzed which BET
protein is the most likely target responsible for the ob-
served JQ1 inhibitory effect on microglial activation. The
BET family is comprised of BET2, BET3, and BET4. A
fourth member, BRDT, is testis-specific [30] and thus
irrelevant to the current study. The expression of BET
family members in the retina has not been previously
reported. We determined BET protein levels by Western
blotting using retinal homogenates collected from rd10
and WT (B6) mice at different ages. Interestingly, BET2
protein levels dramatically decreased from PN14 to
PN24 in B6 mouse retinas, but maintained in rd10
retinas and thus became significantly higher than in B6
mice at PN24 (Fig. 6a). In contrast, either BET3 or BET4
protein levels did not change over age and were equiva-
lent between rd10 and B6 retinas at three age points
(Fig. 6b, c). These results are consistent with a role of
BET2 in retinal degeneration in rd10 mice. In addition,
BET2 immuno-staining is evenly spread out on B6 sec-
tions, but shows a distinct pattern on rd10 sections at
PN18-PN30, i.e., condensed dots in ONL and inner
layers. In contrast, there is no obvious difference of
BET3 or BET4 staining between B6 and rd10 retinal sec-
tions at all ages examined (Fig. 6d, Additional file 1: Fig-
ure S7). We thus focused on BET2 as the most relevant
of the three BETs to microglial activation.
We performed siRNA knockdown to further define
the role of BET2 in microglial activation (Fig. 7). As
BET4 was also implicated in previous studies as a pro-
inflammatory regulator in macrophages [9, 15], we also
knocked down BET4 in N9 cells. Efficient knockdown of
both BET2 and BET4 by specific siRNAs was confirmed
by Western blotting (Fig. 7a, b) as well as qRT-PCR
(Additional file 1: Figure S8). We found that although
BET2 knockdown inhibited LPS-induced expression of
all tested inflammatory cytokine genes (TNFα, MCP-1,
IL-1β, IL-6, and RANTES) by ~50%, BET4 knockdown
did not produce a significant inhibition of expression of
any cytokine except IL-6 (Fig. 7c).
Discussion
Epigenetic modulation is becoming an attractive strategy
for developing new therapeutics. In particular, the BET
epigenetic “reader” family has recently garnered tremen-
dous attention [10], primarily because of the discovery
of highly specific designer inhibitors to these notoriously
“undruggable” regulators [13], some of which quickly
advanced to clinical trials [14]. The BET family has been
recently identified as a prominent player in a growing
list of pathological conditions, predominantly prolifera-
tive and inflammatory diseases [10]. However, whether
BET proteins are involved in retinal degenerative dis-
eases is not known. In this study, we made three main
findings. First, blockade of bromodomains of the BET
family with JQ1 preserves photoreceptor number and
retinal function in the RP model of rd10 mice. Second,
JQ1 treatment suppresses microglial activation in vivo in
Fig. 6 BET2 is upregulated in the rd10 mouse retina compared to B6 WT control. a–c Western blots of retinal homogenates collected from B6 or
rd10 mice at PN14, P21, or PN24 (>6 mice at each time point). Quantification: normalization to β-actin and WT at each time point; mean ± SEM; n
= 3 independent Western blot experiments; *P < 0.05, **P < 0.01 compared to WT control. d Immunostaining of BET2, BET3, and BET4 on paraffin-
embedded retinal sections collected at PN24. Arrow points to dots of condensed staining. Scale bar 50 μm
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the rd10 retina and in vitro under pathogenic stimula-
tion. Third, BET2 is likely a determinant BET family
member and Brom2 appears to be the primary func-
tional domain in the activation of N9 microglial cells. In-
asmuch as microglial activation plays a crucial role in
photoreceptor degeneration, as recently demonstrated in
rd10 mice [6, 7], our results suggest that epigenetic
interference targeting BET proteins (or bromodomains)
may open a new avenue to protect photoreceptors via ef-
fective suppression of microglial activation.
Our findings are novel because we provide the first
evidence for rescue of photoreceptors and inner retina
(see b-wave, Fig. 1) in an inherited retinal degeneration
model by disrupting BET epigenetic readers. Since the
serendipitous discovery of the first-in-class BET inhibi-
tor, JQ1 [13], and the ensuing development of various
analogs [14], studying BET functions in diseases has
become feasible [10]. Most of the recent breakthroughs
surrounding BETs occurred in cancers, inflammatory
diseases, and/or immunological disorders, supporting a
key role of this family in pathogenesis [10, 14]. However,
there are very few reports on BETs in the central ner-
vous system. In fact, to the best of our knowledge, there
is no publication reporting BET functions specifically in
retinal degeneration. Two recent brain studies identified
BET4-mediated transcriptional activation during mem-
ory formation [31] and cocaine-induced neuronal plasti-
city [32]. Another relevant study showed an inhibitory
effect of JQ1 on human umbilical vein endothelial cell
proliferation, migration, and tube formation [33]. While
in this new report, JQ1 was found to inhibit neovascular-
ization in an oxygen-induced retinopathy mouse model,
its effect on retinal degeneration was not investigated.
Therefore, almost nothing is known about BET regula-
tion in retinal degeneration, underscoring the urgency of
research in this area.
While our data show an in vivo role of BETs in micro-
glial activation during retinal degeneration, our finding
is also supported by relevant recent reports. One study
using the BV-2 microglial cell line and RNA sequencing
indicated JQ1 inhibited LPS-stimulated expression of
inflammation- and immunity-related genes [17]. Other
two studies demonstrated suppression of inflammatory
gene expression by blocking the BET family in LPS-
stimulated macrophages [9, 15], which are monocyte-
derived immune cells with similarities to microglia [16].
Most recently, anti-inflammatory effect of BET inhib-
ition was observed in the mouse brain [34]. Our study is
distinct from these reports in that our data provide in
vivo evidence for the suppression of microglial activation
via BET inhibition specifically in the retina undergoing
neurodegenerative pathology. We observed dramatically
reduced microglial infiltration into the ONL and subret-
inal regions in JQ1-treated rd10 retinas versus vehicle
control-treated retinas. Moreover, gene expression deter-
mination using microglia directly isolated from rd10 ret-
inas confirmed that JQ1 treatment reduces microglial
inflammation in the retina. Significantly, we observed
that JQ1 treatment preserves photoreceptors in the rd10
model. Based on recent reports that microglial activation
potentiates photoreceptor demise in rd10 mice [6, 7], we
infer JQ1 protects photoreceptors in large part by sup-
pressing microglial activation. In addition, we found JQ1
also reduces apoptosis in the rd10 photoreceptor layer.
Our data cannot distinguish whether this was a direct ef-
fect on the apoptotic program in photoreceptors or a
secondary effect via inhibition of microglial activation
which promotes photoreceptor apoptosis [6]. Since it is
not technically feasible to homogenously isolate and cul-
ture retinal photoreceptors, it will require future investi-
gation in photoreceptor-specific BET knockout mice to
definitively determine whether BETs regulate the
apoptotic program directly in photoreceptors. How-
ever, the proposition of direct BET regulation in
photoreceptor cells in this context is undermined by
little positive staining of the BETs (if any above non-
specific background) in the ONL photoreceptor
Fig. 7 BET2 knockdown in N9 microglial cells inhibits inflammatory
cytokine expression. N9 cells were infected with lentivirus expressing
BET2 or BET4 siRNAs for 3 days and then GFP-positive (infected) cells
were purified by flow sorting and cultured for 2–3 days. The cells
were either used for Western blotting or stimulated with LPS (1 μg/
ml) for 2 h and then subjected to qRT-PCR. a, b Western blots
showing BET protein knockdown. Quantification: mean ± SEM; n = 3
experiments; *P < 0.05, **P < 0.01 compared to scrambled siRNA. c
qRT-PCR determination of inflammatory cytokine mRNAs. Quantifica-
tion: mean ± SEM; n = 3 experiments; *P < 0.05, **P < 0.01 compared
to scrambled siRNA + LPS
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nuclei. Nevertheless, our results support a promising
strategy to protect photoreceptors in RP via pharma-
cological inhibition of the BET family, a distinct
group of epigenetic readers.
It is worthnoting that despite a reported short half life
(~1 h) of JQ1 after intraperitoneal injection into mice
[13], in our experiments, intravitreally delivered JQ1
produced photoreceptor protection even 10 days after
injection. There are at least two plausible explanations
for this: (1) The drug delivered into the eye, an isolated
organ, may not immediately enter the circulation thus
evading quick metabolic degradation. (2) Even if JQ1
binds BET proteins only at early times, consequential
changes in gene expression and downstream signaling
could have a lasting effect. In future investigations,
further prolonged therapeutic benefits may be achieved
by using a JQ1 derivative with improved bioavailability
(or half life). Moreover, since higher doses of injected
JQ1 did not significantly improve its therapeutic effect
(Additional file 1: Figure S4), a more sophisticated deliv-
ery method should be applied, e.g., using nanoparticles
to extend drug release time or an osmotic pump to pro-
vide continued release.
While a recent study by Jung et al. showed a promin-
ent role of JQ1 in suppressing LPS-induced BV-2 cell
inflammatory gene expression [17], it is interesting to
note distinct outcomes of our study using N9 cells,
another commonly used microglial cell line [35]. We
found that blocking BET activity with JQ1 effectively ab-
rogated LPS-stimulated upregulation of TNFα, IL-1β,
and MCP-1 (CCL2). Elevation of TNFα and IL-1β is a
hallmark of neuroinflammation, which is a critical eti-
ology in neurodegenerative diseases [35]. MCP-1, a
chemoattractant and an inflammatory cytokine, plays a
crucial role in microglial migration/infiltration and
neuroinflammatory disorders [8]. Using BV-2 cells, Jung
et al. also observed JQ1 inhibition of LPS-induced tran-
scription of IL-1β and MCP-1, but not TNFα [17].
Moreover, whereas our data of N9 cells show a JQ1 in-
hibitory effect on the expression of IL-6 and RANTES,
two important inflammatory factors associated with
microglial activation, they are absent from the list of
JQ1-downregulated genes in BV-2 cells [17]. Supporting
our results from the N9 cell line, we also observed JQ1-
effected downregulation of the foregoing group of
inflammatory cytokines in primary mouse brain micro-
glial cells as well as primary microglia isolated and puri-
fied from rd10 mouse retinas. Together with our unique
data on JQ1 inhibition of N9 cell proliferation and
migration (Fig. 5b, c), our results demonstrate a previ-
ously uncharacterized broad potency of BET inhibition
in blocking microglial activation. As BV-2 is a rat micro-
glial cell line and N9 is derived from mouse brain micro-
glia [23, 35], the discrepancy between our study and the
previous report by Jung et al. [17] may arise from differ-
ent origins of these two microglial cell lines.
Another distinction between the two studies is that in
the previous report [17], it remained unknown as to
which BET member or bromodomain plays a predom-
inant role in microglial activation. Our siRNA experi-
ments suggest that BET2 is the key regulator in
microglial activation. There are several lines of evidence
supporting this conclusion. First, BET2 knockdown by
siRNA abolished LPS-induced expression of all tested
inflammatory cytokines whereas BET4 knockdown did
not produce a prominent effect. Second, BET2 protein
levels in the retina (determined by Western blotting)
were markedly increased at PN24 in rd10 mice com-
pared to B6 mice, an age coinciding with the peak time
of retinal microglial activation and photoreceptor de-
generation in rd10 mice [6]. Third, consistent with the
Western blot result, immuno-histochemistry on PN24
rd10 retinal sections revealed dots of condensed BET2
staining in the ONL and INL regions, a pattern distinct
from that on B6 retinal sections. In contrast, neither
BET3 nor BET4 staining shows a difference between
rd10 and B6 retinas. Last, BET2 has been shown to be
essential in LPS-induced inflammatory cytokine pro-
duction in bone marrow-derived macrophages [15]. In
this previous study, siRNA knockdown of BET2 or
BET4 suppressed the expression of major inflammatory
cytokines, including TNFα, IL-6, and MCP-1, and both
BET2 and BET4 were found to associate with pro-
moters of those genes. However, in our study using N9
microglial cells, knockdown of BET4 did not inhibit
LPS-stimulated expression of TNFα, IL-1β, MCP-1, and
RANTES. This difference in the two studies highlights
the cell type and context dependence of BET regula-
tion, which has been repeatedly observed in recent re-
ports (see review [12]). On the other hand, knockdown
of BET4 effectively blocked LPS stimulation of IL-6
transcription but not of other tested cytokines (Fig. 7c).
This result suggests differential BET2 and BET4 regula-
tions of inflammatory cytokine genes in microglia. We
cannot rule out the possibility that BET4 may regulate
other inflammatory cytokine genes not tested in the
current study.
As JQ1 is a pan-specific inhibitor that blocks both
Brom1s and Brom2s in all BET members, we also
explored which bromodomain is the likely functional site
of the observed JQ1 effects, using two inhibitors specific
to either Brom1s or Brom2s in all BETs. Our data
suggest that Brom2 may play a dominant role in BET-
directed microglial activation. To our knowledge, differ-
ential roles of the two BET bromodomains in inflamma-
tory gene expression have not been previously
addressed. To determine definitively whether Brom2 in
BET2 is the primary functional domain responsible for
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retinal microglial activation, future investigations should
use microglia-specific BET knockout or bromodomain-
inactivating mutant mice. Nevertheless, our results
contribute new insights into the differential roles of BET
family members and their bromodomains in microglial
inflammatory responses. This progress is significant in
regard to future development of RP-preventing thera-
peutics with maximal efficacy and minimal side effects,
which may be achieved via precise BET targeting. In fact,
development of BET protein- or bromodomain-selective
inhibitors represents an active research area [24].
As supported by recent discoveries on BET epigenetic
mechanisms, BET protein(s) may play a “master” regula-
tor role during microglial activation. Genome-wide
investigations reveal that a specific cell state is defined
by the combination of only a small number of transcrip-
tion factors and super-enhancers [11, 36, 37]. In
response to pathogenic cues, transcription factors and
super-enhancers re-assemble at and activate the expres-
sion of a select group of genes which act in concert to
drive cell state transformation [11, 38, 39]. BET proteins
play a critical role by coupling this transcription-
activating assembly to RNA polymerase II [12]. When
BET is displaced from epigenetic marks (acetylated-ly-
sines) by a bromodomain blocker such as JQ1, the as-
sembly collapses [12]. Thus, BET proteins and/or
bromodomains provide sensitive pharmacological targets
for interventions. This mechanism may underlie the
profound inhibitory effect of JQ1 on microglial activa-
tion. Our future studies on BET-associated transcription
factors and super-enhancers are expected to elucidate
this possible scenario in retinal microglial activation.
Conclusions
We have identified a prominent role of the BET epi-
genetic reader family in photoreceptor degeneration
and retinal microglial activation in the rd10 RP model.
Our study advocates a BET-targeted novel strategy for
effective treatment of RP. The recent development of
BET inhibitors represents a new chapter in “epigenetic
therapy” because they are the first successful pharma-
cological interference with the class of epigenetic
“readers” [14]. Only a few years after the first descrip-
tion of BET-specific inhibitors [9, 13], several drugs
are already in clinical trials with encouraging results
[10, 40]. Intriguingly, recent studies indicate that
blockade of BETs, seemingly general transcriptional
co-activators, does not suppress genes globally, but ra-
ther, suppresses only over-active genes, which are
often pathogenic [10–12]. This specificity of BET-
governed regulations is a solid foundation for future
translation of a BET-targeted therapeutic paradigm.
As microglial activation, or pathogenic cell state
transformation, is a hallmark of multiple neuro-
degenerative diseases [8], our study may have an im-
portant impact beyond the rd10 RP model and retinal
degenerative diseases.
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